LMC provides background and success outlook on 14 leading senolytic companies
Longevity Marketcap - 15-Dec-2020Comprehensive review of companies' clinical and financial state of play
Senolytic Therapeutics (Senolytx)
Pharmaceutical company that develops a novel class of medicines by targeting damaged cells.
Senolytic Therapeutics is a operator of a pharmaceutical company intended to develop medicines and therapeutics for patients affected by age-related diseases. The company's medicines target and eliminate damaged cells, enabling healthcare providers to improve the lives of those affected by diseases associated with aging.
Visit website: http://senolytx.com/
Details last updated 04-May-2019
People at Senolytic Therapeutics (Senolytx)
Senolytic Therapeutics (Senolytx) News
Nature Biotechnology reviews the state of play of senolytics
Nature Biotechnology - 12-Nov-2020In August, Unity announced that its lead drug candidate had failed to beat a placebo in reducing ...
Labiotech gathers feedback from European biotechs on Unity failure
Labiotech - 28-Aug-2020General feeling that failures are bound to happen - but that their approaches can succeed
LEAF report from the Longevity Leaders Conference
Lifespan.io (LEAF) - 06-Feb-2019Encouraging signs from big companies - more interviews to follow
